T1	Premise 1093 1311	Patients in the TC arm showed better means scores after treatment on overall QoL (P = .012), physical functioning (P = .012), role functioning (P = .005), and cognitive functioning (P = .024), compared with the PT arm.
T2	Premise 1312 1536	Concerning symptom experience, patients undergoing TC showed less nausea and vomiting (P < .001), less appetite loss (P < .001), and less fatigue (P = .033) after completion of treatment compared with patients undergoing PT.
T3	Claim 1537 1610	The TC regimen achieved better QoL outcomes compared with the PT regimen.
T4	Claim 1611 1734	Thus, clinicians may consider replacing cisplatin with carboplatin when treating ovarian cancer patients with chemotherapy.
R1	Support Arg1:T3 Arg2:T4	
R2	Support Arg1:T2 Arg2:T3	
R3	Support Arg1:T1 Arg2:T3	
